How are new embryo genome editing advances reigniting ethical debates in biopharma?

Recent progress in embryo genome editing is renewing long‑standing ethical concerns over how far human genetic modification should go. As feasibility improves, regulators face pressure to distinguish therapeutic DNA correction from enhancement, likely prompting stricter oversight, slower clinical adoption, and new policy guidance expected by 2026.